Abstract 5P
Background
Glioblastoma is the most common and aggressive type of primary brain tumor. The prognosis for patients diagnosed with GBM is unfortunately very poor, with a median overall survival of only 14 months and very limited options for treatment. Several studies have detected a mutation in the isocitrate dehydrogenase 1 (IDH1) gene as a molecular marker associated with improved survival in patients with glioblastoma, but the evidence is inconsistent and inconclusive. We conducted this meta-analysis to investigate the link between IDH1 mutation and overall survival in glioblastoma patients.
Methods
A thorough literature search of databases (PubMed, Scopus, Cochrane, Embase, and Web of Science databases) yielded five studies involving 541 glioblastoma cases that reported overall survival by IDH1 mutation status. The meta-analysis was conducted using Cochrane review manager V 5.4.
Results
Our meta-analysis encompassed five studies, involving a total of 541 patients (480 with IDH1 wild type and 61 with mutant type). Among these, three studies focused on patients with recurrent glioblastoma (GBM), while two studies involved newly diagnosed GBM cases. The treatment modalities varied, with one study employing alkylating agents, two studies utilizing tyrosine kinase inhibitors, one study combining immunotherapy with alkylating agents, and one study not specifying the treatment. The pooled hazard ratio (HR) was 2.37 (95% CI 1.81–3.12; p < 0.001; I2=0%), indicating a significant association between IDH1 mutation and prolonged overall survival in glioblastoma patients, irrespective of the therapeutic intervention. For recurrent GBM, the pooled HR was 2.28 (95% CI 1.72–3.03; p < 0.001; I2=0%). Additionally, in the context of newly diagnosed GBM, the pooled HR was 3.06 (95% CI 0.48–19.63; p < 0.001; I2=39%).
Conclusions
This study clearly demonstrates that IDH1 mutation in patients with glioblastoma is a favorable prognostic factor for overall survival, regardless of the treatment modality or disease stage. The findings suggest that IDH1 mutation status should be considered in the clinical management and stratification of glioblastoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.